Sanofi Withdraws Some Health Centers’ 340B Pricing at Contract Pharmacies

Sanofi headquarters
Sanofi has recently denied some health centers access to 340B pricing at contract pharmacies after saying they did not conform to Sanofi's policy.
Drug manufacturer Sanofi recently started denying access for some health centers to 340B pricing at contract pharmacies after previously saying [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Merck Offering Refunds to 340B Covered Entities

Merck
Merck is the first drug manufacturer to announce it is issuing refunds to 340B providers in 2024.
Drug manufacturer Merck recently announced that it owes refunds to 340B covered entities for purchases of 17 products during the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Sources Cited in Drugmakers’ Brief Question Accuracy in High-Profile 340B Patient Definition Case

Genesis
Genesis Health Care successfully challenged HRSA's 340B patient definition in the U.S. District Court for the District of South Carolina.
Inaccurate points were ascribed to 340B advisers and service providers in a recent legal filing by four drugmakers as part [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Janssen Issuing Refunds for 340B Overcharges

Janssen
Janssen Biotech is paying refunds for overcharges on certain 340B drugs purchased in the third quarter of 2020.
Drug manufacturer Janssen Biotech recently determined that it owes or may owe refunds to some 340B covered entities. The refunds [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

PhRMA to Federal Appeals Court: Arkansas Enforcing 340B Contract Pharmacy Law; Seventh Drugmaker Sues Over IRA

Eighth Circuit Court
PhRMA filed a citation to notify the U.S. Eighth Circuit Court of Appeals in St. Louis that Arkansas is enforcing its 340B contract pharmacy law.
The drug industry group challenging the legality of Arkansas’ 340B contract pharmacy law, notified a federal appeals court that the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Tolmar Providing Refunds for Five Years of 340B Overcharges

Drugmaker Tolmar said it will refund 340B covered entities for overcharges on certain generic dermatologic products.
Drug manufacturer Tolmar recently said it plans refunds to 340B covered entities for overcharges on seven generic dermatologic products purchased [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

UCB Tightens 340B Contract Pharmacy Restrictions for Hospitals

UCB signage and building
UCB announced it will tighten its existing 340B contract restrictions on hospitals beginning Oct. 2.
Belgium drug maker UCB will add restrictions on 340B contract pharmacy use for hospitals starting Oct. 2, according to a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

EMD Serono Extends Hospital 340B Contract Pharmacy Conditions to All Products

EMD Serono wordmark on building
EMD Serono announced extended 340B contract pharmacy restrictions for hospitals in a manufacturer notice on Sept. 1.
Drug manufacturer EMD Serono (EMDS) today announced 340B contract pharmacy restrictions for hospitals will expand Oct. 1 to all of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Arkansas Initiates First-in-the-Nation Enforcement of 340B Contract Pharmacy Law

Arkansas Insurance Department office sign
The Arkansas Insurance Department will imminently enforce a state 340B contract pharmacy law following a key federal appeals court decision.
The Arkansas Insurance Department (AID) has formally notified at least four drugmakers that they are in potential violation of a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Boehringer Ingelheim Sues to Block Medicare Price Negotiations

Boehringer Ingelheim headquarters
Boehringer Ingelheim sued the federal government to block Medicare price negotiations shortly before its diabetes drug was picked for negotiations.
Drug maker Boehringer Ingelheim (BI) sued the federal government to block Medicare price negotiations shortly before the Department of Health [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report